All articles — 4193 total
AGL enters its Q1 2026 earnings release tomorrow with the sharpest analyst signal of the pre-print period arriving just hours ago: JP Morgan's Lisa Gill downgraded the stock to Underweight with a $21 target — a direct…
Design Therapeutics arrives at its May 8 Q2 earnings call on a genuine high. The stock jumped 23% on April 28 after Q1 EPS of -$0.29 beat estimates by $0.05 and the company narrowed its net loss. It has since pulled…
Coinbase Global reports Q1 2026 results on May 7 with short sellers firmly entrenched and options traders adding hedges into a stock that has already reclaimed a fifth of its value in a month. Short interest is the…
Valaris heads into its May 6 earnings release with a notable divergence between options traders turning more defensive and short sellers quietly reducing exposure. The clearest pre-earnings signal is in options. The…
AppLovin heads into its May 6 Q1 print with options sentiment at its most cautious in twelve months — a sharp contrast to a stock that has rallied hard. The options signal is the clearest tell in the setup. The…
Nuvation Bio heads into its May 8 earnings report with short sellers making a clear statement — and options traders ignoring them entirely. Short interest has become the dominant feature of the positioning picture. At…
CLNN heads into its May 8 earnings call riding an FDA-driven momentum spike — the most significant catalyst update in the company's recent history. The FDA news is the story. On May 4, Clene announced the agency…
Damora Therapeutics walks into its May 7 earnings report carrying two distinctly uncomfortable facts: a CFO who just stepped down and a short interest that has tripled in six weeks. The headline from Monday — CFO Lori…
BDSX reports Q1 2026 results on May 8 with the stock carrying a 25% monthly loss into the print — yet showing signs of near-term stabilisation. The price action tells a split story. Shares fell sharply through April to…
UTZ heads into its May 6 earnings report with short sellers rapidly unwinding what had been a materially elevated position — yet the analyst community remains firmly on edge. Short interest peaked at roughly 12.8% of…
Viatris heads into its May 7 Q1 earnings report with short sellers quietly adding exposure — even as the stock posts its best month in some time. The most notable positioning shift is in short interest. Bears have…
IAC Inc. heads into its Q1 2026 results today with a wave of upward analyst revisions at its back — and the clearest question is whether the fundamentals can validate the optimism. The analyst case for IAC has…
COMPASS Pathways reports Q1 2026 results on May 7 after a month that has completely re-priced the stock — and the short-side has scrambled to keep up. Options positioning has actually turned more bullish into the…
Adeia heads into its May 6 earnings call with the headline numbers already out — and a leadership bombshell overshadowing a solid beat. Q1 results landed after the close on May 4. Adjusted EPS came in at $0.38, beating…
ORIC Pharmaceuticals enters today's earnings report with nearly 30% of its free float sold short — a meaningful bearish overhang for a clinical-stage biotech that has rallied 8% over the past month. Short sellers are…
The Baldwin Insurance Group heads into Tuesday's earnings report with short sellers more active than they have been in months — and options traders showing their most defensive posture of the year. Short interest has…
urban-gro, Inc. heads into its May 6 earnings print as one of the most expensive stocks to borrow in the market — a signal that the lending dynamics around this micro-cap are more dramatic than the short interest level…
Ocugen heads into its Q1 2026 earnings call today heavily scrutinised by short sellers, with the stock's lending dynamics forming the central narrative for the session. Short interest is the dominant signal here. At…
MIRM enters its May 6 Q1 earnings report with a substantial short position and a stock that just broke sharply higher — a combination that makes Thursday's release genuinely consequential for both sides of the…
A concentrated buyer has loaded up on RPAY shares at depressed prices — and those positions now face their first test as the company reports Q1 2026 earnings on May 8. The most striking feature of the setup is the…
